Comparison of EQ-5D and SF-6D utilities in mental health patients by Lamers, L.M. et al.
HEALTH ECONOMICS
Health Econ. 15: 1229–1236 (2006)
Published online 20 April 2006 in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/hec.1125
Comparison of EQ-5D and SF-6D utilities inmental health
patients
L. M. Lamersa,b,*, C. A. M. Bouwmansa, A. van Stratenb, M. C. H. Donkerb and L. Hakkaarta
a Institute for Medical Technology Assessment bv, Erasmus University Medical Center, Rotterdam, The Netherlands
bDepartment of Health Policy and Management, Erasmus University Medical Center, Rotterdam, The Netherlands
Summary
Various preference-based measures of health are available for use as an outcome measure in cost–utility analysis.
The aim of this study is to compare two such measures EQ-5D and SF-6D in mental health patients.
Baseline data from a Dutch multi-centre randomised trial of 616 patients with mood and/or anxiety disorders were
used. Mean and median EQ-5D and SF-6D utilities were compared, both in the total sample and between severity
subgroups based on quartiles of SCL-90 scores. Utilities were expected to decline with increased severity.
Both EQ-5D and SF-6D utilities diﬀered signiﬁcantly between patients of adjacent severity groups. Mean utilities
increased from 0.51 at baseline to 0.68 at 1.5 years follow-up for EQ-5D and from 0.58 to 0.70 for SF-6D. For all
severity subgroups, the mean change in EQ-5D utilities as well as in SF-6D utilities was statistically signiﬁcant.
Standardised response means were higher for SF-6D utilities.
We concluded that both EQ-5D and SF-6D discriminated between severity subgroups and captured
improvements in health over time. However, the use of EQ-5D resulted in larger health gains and consequent
lower cost–utility ratios, especially for the subgroup with the highest severity of mental health problems. Copyright
# 2006 John Wiley & Sons, Ltd.
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Introduction
During the past decades, quality of life has become
an important health outcome in economic evalua-
tions. In cost–utility analysis, outcomes are
typically measured in Quality-Adjusted Life Years
(QALYs). This outcome measure captures both
gains from reduced morbidity (quality) and
mortality (quantity). The quality adjustment is
based on a set of weights, called utilities, which
reﬂect the desirability of the health states. For each
possible health state, utilities should be measured
on an interval scale, where 1 refers to full health
and 0 refers to death [1]. Additionally, negative
utilities may occur if very severe health states are
evaluated as being worse than death [2]. Measur-
ing utilities is complex and time-consuming. For
this reason, generic preference-based instruments
like EuroQol-5D (EQ-5D) [3], Short Form-6D
(SF-6D) [4] or the Health Utility Index (HUI) [5,6]
are attractive and widely used for cost–utility
analysis.
The EQ-5D descriptive system consists of ﬁve
dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) with
three levels each (no problems, some problems
and extreme problems), thus deﬁning 243 (35)
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distinct health states. In 1993, the Measurement
and Valuation of Health (MVH) Group at the
Centre for Health Economics in York conducted a
large-scale national (UK) study to elicit direct
valuations of 3395 persons from the general public
for 42 EQ-5D health states using the time trade-oﬀ
method. Regression techniques were applied to
these direct valuations to interpolate values for the
200 states for which no direct valuations had been
elicited [7,8]. The resulting set of regression
coeﬃcients or tariﬀ (the MVH A1 tariﬀ) is widely
used to calculate utilities for EQ-5D health states
for cost–utility analyses of health care pro-
grammes and treatments. The utilities ranged from
0.59 to 1.00 [7].
Recently, the Sheﬃeld Health Economic Group
derived a preference-based measure of health from
the SF-36 [4]. The SF-36 generates scores on eight
dimensions of health: general health, physical
functioning, role limitations (role-physical and
role-emotional), social functioning, bodily pain,
vitality and mental health. Originally the SF-36
was not developed for use in economic evaluations
since it did not incorporate preference weights in
its scoring system. The new preference-based
measure, known as the SF-6D, is derived from
11 items of the SF-36 and is composed of six
dimensions of health with four to six levels each.
The SF-6D thus describes a total of 18 000 possible
health states. Of these, 249 states were directly
valued by a representative sample of 611 members
of the general UK population, using the standard
gamble method. Like the EQ-5D, regression
models were estimated to predict single utility
scores for all possible SF-6D health states, ranging
from 0.30 to 1.00 [4].
Since the EQ-5D and the SF-6D diﬀer in their
descriptive systems and used diﬀerent valuation
methods to estimate their sets of utility scores,
completion of both instruments by the same
patient might be expected to result in diﬀerent
utilities. In other words, the diﬀerent outcomes of
cost–utility analyses may depend on the prefer-
ence-based measure of health used. Brazier et al.
[9] compared utility scores on the EQ-5D and the
SF-6D in seven diﬀerent patient groups. They
found a substantial agreement between the mean
utilities with on average some higher values
generated by SF-6D. However, diﬀerences be-
tween the EQ-5D and the SF-6D preferences
varied by patient group. Longworth and Bryan
[10] compared utilities from both instruments in
liver transplant patients. While the EQ-5D scores
showed signiﬁcant changes before and 12 months
after transplantation, the SD-6D was not able to
capture changes in utility following transplanta-
tion. The authors concluded that the SF-6D
appeared not to describe health states at the lower
end of the utility scale (close to or below zero),
thus underestimating the magnitude of improve-
ment in quality of life in this particular patient
group. However, Longworth and Bryan [10]
expected that the SF-6D to be more sensitive to
smaller changes towards the top of the utility scale
(close to 1) compared to EQ-5D.
Until now, no information about possible
diﬀerences between the EQ-5D and the SF-6D
utilities in patients with mental health problems
was available, as previous studies did not include
this population. The aim of this paper was to
compare the EQ-5D and SF-6D utilities across
patients suﬀering from mood and anxiety dis-
orders, the most common mental health problems.
To our knowledge, no study has yet compared
diﬀerences in utilities on the EQ-5D and the
SF-6D between subgroups of patients with a
diﬀerent degree of severity of illness. A second
objective of our study was to assess the ability of
the EQ-5D and SF-6D to discriminate between
subgroups of patients by severity.
Methods
Data
Data were extracted from a large multicentre
randomised trial in Mental Health Care Centres
(MHC) in the Netherlands. This naturalistic trial
assessed the cost-eﬀectiveness of Brief Therapy
(BT) compared to Cognitive Behavioural Therapy
(CBT) and Care As Usual (CAU) in patients with
mood and/or anxiety disorders (Hakkaart-van
Roijen L, van Straten A, Al MJ, Rutten FFH,
Donker MCH. The cost utility of brief psycholo-
gical treatment for depression and anxiety. Br J
Psychiatry, accepted for publication). Patients
aged 18–65 with a diagnosis of a major depressive
disorder, dysthymic disorder, panic disorder,
social phobia, or generalised anxiety were in-
cluded. Disorders were classiﬁed according the
Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) [11]. Comor-
bidity in these patients associated with other
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psychiatric diagnoses was allowed, except for
psychotic or bipolar disorder (Hakkaart-van
Roijen et al., accepted for publication). The
patient population was representative for the
patients treated at MHCs in the Netherlands.
The primary outcome was the prevalence of mood
and anxiety disorders, as measured by the Com-
posite Diagnostic Interview (CIDI). Secondary
outcomes that were measured consisted of the
Symptom Checklist (SCL-90) [12] and health-
related quality of life measured by EQ-5D and
SF-36.
The SCL-90 is a valid instrument to measure
severity of neurotic illness [13,14]. It consists of 90
psychological symptoms, which are rated on a ﬁve-
point scale, ranging from 1 (no distressed by the
symptom) to 5 (extremely distressed by the
symptom). By summing the item scores, a total
score can be obtained that ranges from 90 (no
distress) to 450 (extremely distressed), with 118
representing the mean score for the general Dutch
population. The SCL-90 scores were used to a
measure of severity of mental health problems.
Four severity subgroups were formed using the
quartiles of the SCL-90 scores.
Baseline data were available for 643 patients.
Six-hundred and sixteen patients completed all the
questions on the EQ-5D, SF-6D and SCL-90. The
baseline data from these patients were used in the
comparison of the EQ-5D and the SF-6D. The
mean age was 36.8 years (median 35) and 61.2% of
these patients were women. Complete EQ-5D and
SF-6D were available at 1 and 1.5 year follow-up
for 355 and 326 patients, respectively (Hakkaart-
van Roijen et al., accepted for publication).
Analyses
First, an overall comparison of the patient’s self-
rated health on the dimensions of the EQ-5D and
the SF-6D was made. The degree of agreement
between the dimensions of the EQ-5D and the
SF-6D was examined using Spearman’s rank
correlation. Next, EQ-5D and SF-6D utilities were
calculated and compared. The EQ-5D utilities
were based on the MVH A1 tariﬀ [7]. The SF-36
scores were translated into SF-6D utilities using
the algorithm developed by Brazier et al. [4].
To assess the discriminative ability for severity
of illness, the mean EQ-5D and SF-6D utilities
were compared in severity subgroups based on the
SCL-90 scores subgroups. The utilities of EQ-5D
and SF-6D were also analysed separately for
adjacent severity subgroups. We hypothesised that
preferences would decrease with increasing sever-
ity. Diﬀerences in preferences between the sub-
groups on both the EQ-5D and the SF-6D were
analysed using a one-sided student’s t-test. Diﬀer-
ences between EQ-5D and SF-6D within sub-
groups were analysed using a paired t-test.
For the severity subgroups, the mean improve-
ments in EQ-5D and SF-6D utilities at 1 and 1.5
years follow-up i.e. follow-up utility minus base-
line utility, were assessed. As a statistical measure
of responsiveness the standardised response mean
(SRM) was calculated using the following for-
mula: SRM ¼ mean diﬀerence/standard deviation
of diﬀerence.
Results
Overall comparison
An inspection of the distribution of patients’
scores across the dimensions of both instruments
revealed that, in general, more respondents re-
ported having no limitations on the EQ-5D
compared to the SF-6D. Furthermore, fewer
respondents were placed in the worst category
(extreme problems) of the EQ-5D dimensions.
Tables 1 and 2 show the self-reported health scores
on the dimensions of EQ-5D and SF-6D at
baseline. Patients responded diﬀerently on related
dimensions of the instruments. The greatest
diﬀerences occurred between the EQ-5D dimen-
sions mobility and self-care and the related SF-6D
dimension physical functioning. Seventy-eight
percent of the respondents appeared to have no
mobility problems and 93.5% had no problems
with self-care. By contrast, only 18% of the
respondents reported having no limitations in
physical functioning on the SF-6D. Furthermore,
23% of the patients had no problems in perform-
ing usual activities (EQ-5D), while, respectively,
10.9 and 6.2% reported no limitations in the
related SF-6D dimensions role limitation and
social functioning. Surprisingly, given the popula-
tion studied here, a rather high degree of
divergence was also seen between the dimensions
of both instruments covering mental functioning:
almost 65% reported having problems most of the
time or all of the time due to mental health (level 4
Comparison of EQ-5D and SF-6D Utilities inMental Health Patients 1231
Copyright # 2006 John Wiley & Sons, Ltd. Health Econ. 15: 1229–1236 (2006)
DOI: 10.1002/hec
and 5) on the SF-6D, compared to 33% who
reported having extreme problems on the anxiety/
depression dimension of the EQ-5D.
Rank correlations between the dimensions of
the EQ-5D and the SF-6D, based on the patients’
self-reported health, are presented in Table 3.
Related dimensions based on the descriptive
systems of both instruments are indicated in bold.
One would expect to ﬁnd the strongest correlations
between the related dimensions on EQ-5D and
SF-6D. Indeed, the highest correlation of 0.57 was
found between the dimensions pain/discomfort
(EQ-5D) and pain (SF-6D), followed by the
correlation between the EQ-5D dimension anxi-
ety/depression and the SF-6D dimension mental
health. A low correlation was observed between
the dimensions self-care and physical functioning.
In the total population, the mean EQ-5D and
SF-6D utilities were 0.518 (SD 0.29) and 0.575 (SD
0.10), respectively. The median scores were 0.689
and 0.567. Both mean and median EQ-5D and SF-
6D utilities were signiﬁcantly diﬀerent.
Comparison by severity
The study population was divided into four
severity subgroups based on the quartiles of
SCL-90 scores. The mean SCL-90 scores for these
subgroups were 151, 198, 241 and 302. The mean
Table 1. Distribution of EQ-5D scores per dimension ðn ¼ 616Þ
Level
Mobility
(%)
Self-care
(%)
Usual activities
(%)
Pain/discomfort
(%)
Anxiety/depression
(%)
1. No problems 78.6 93.5 23.1 24.0 7.0
2. Some problems 20.3 6.2 69.2 66.2 59.6
3. Extreme problems 1.1 0.3 7.8 9.7 33.4
Table 2. Distribution of SF-6D scores per dimension ðn ¼ 616Þ
Level
Physical
functioning
(%)
Role
limitation
(%)
Social
functioning
(%)
Pain
(%)
Mental
health
(%)
Vitality
(%)
1 (no limitations) 18.0 10.9 6.2 16.4 0.3 1.0
2 21.6 5.0 10.7 10.4 1.8 6.2
3 19.5 33.3 34.4 29.5 33.1 31.3
4 8.4 50.8 32.8 23.2 45.3 44.5
5 30.0 NA 15.9 13.8 19.5 17.0
6 2.4 NA NA 6.7 NA NA
NA, not applicable.
Table 3. Correlationsa between EQ-5D and SF-6D dimensions
EQ-5D dimension
SF-6D dimension Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
Physical functioning 0.305 0.161 0.194 0.309 0.058b
Role limitations 0.240 0.182 0.329 0.245 0.157
Social functioning 0.149 0.186 0.342 0.188 0.296
Pain 0.353 0.234 0.323 0.570 0.210
Mental health 0.105 0.081 0.202 0.112 0.415
Vitality 0.128 0.157 0.272 0.182 0.282
aCorrelations between related dimensions are indicated in bold.
bNot statistically diﬀerent from zero (p>0.05).
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number of DSM-IV diagnoses increased with
severity from 1.35 in the ﬁrst quartile to 2.35 in
the fourth quartile. Of all patients, almost half had
been diagnosed with a single disorder, 34% had
two and over 19% of the patients had three or four
diagnoses.
The mean and median utilities for severity
subgroups are presented in Table 4. Overall, the
SF-6D utilities were 0.057 higher than the mean
EQ-5D utilities for the total population. The mean
diﬀerence per severity subgroup ranged from 0.06
higher EQ-5D utilities in the low severity sub-
groups formed by the ﬁrst quartile of SCL-90
scores to 0.21 lower EQ-5D utilities in the high
severity subgroup formed by the fourth quartile of
SCL-90 scores. The diﬀerences in mean EQ-5D
and SF-6D utilities were statistically signiﬁcant in
all subgroups except for the subgroup formed by
the second quartile of SCL-90 scores. Larger
variances were found in the utilities on the
EQ-5D compared to the SF-6D utilities.
The EQ-5D and SF-6D utilities were compared
separately in adjacent severity subgroups. Both
mean and median EQ-5D utilities decreased as
severity increased. A relatively high diﬀerence was
seen in the EQ-5D utilities between the subgroups
formed by the third and fourth quartile of SCL-90
scores. Mean EQ-5D utilities diﬀered signiﬁcantly
between all subgroups. The median EQ-5D
utilities were systematically higher than the mean
utilities with the exception of the median score in
the highest severity subgroup. Similarly, the mean
utilities of the SF-6D decreased with severity. Both
mean and median utilities showed statistically
signiﬁcant diﬀerences between adjacent severity
subgroups. The SF-6D median utilities were about
the same or lower than the mean utilities.
The patterns of the EQ-5D and the SF-6D
utilities across the severity subgroups are shown
in Figure 1.
The changes in utilities from baseline until 1
year and 1.5 years follow-up and the SRMs are
presented in Table 5. For this analysis the data of
355 and 326 patients, respectively, with complete
EQ-5D and SF-6D follow-up data were used. The
mean EQ-5D and SF-6D utilities at baseline in the
severity subgroups with complete follow-up were
comparable with those in Table 4 for the total
study population at baseline. In line with the
results of the outcomes used in the clinical study,
signiﬁcant diﬀerences were found between the
baseline and follow-up utilities on both instru-
ments (Hakkaart-van Roijen et al., accepted for
publication). Overall, mean EQ-5D utilities in-
creased from 0.513 at baseline to 0.680 after a
1.5-year follow-up and the SF-6D utilities in-
creased from 0.577 to 0.701. The mean improve-
ment in EQ-5D utilities was lower than for the SF-
6D utilities in the low severity subgroup and
higher for the two subgroups with the highest
Table 4. Mean, median, standard deviation of EQ-5D and SF-6D utility scores per severity subgroup based on
SCL-90 scores
Severity subgroups based on SCL-90 scores N Mean SD Median
1st quartile (scores 95–178)
EQ-5D index 0.701n 0.179 0.725n
SF-6D index 155 0.645n 0.092 0.626n
2nd quartile (scores 179–218)
EQ-5D index 154 0.597n 0.237 0.689n
SF-6D index 0.595n 0.075 0.591n
3rd quartile (scores 219–263)
EQ-5D index 153 0.480n 0.267 0.620n
SF-6D index 0.561n 0.074 0.547n
4th quartile (scores 264–404)
EQ-5D index 154 0.294 0.308 0.255
SF-6D index 0.499 0.081 0.494
SD, standard deviation.
nStatistically signiﬁcant diﬀerence between the group and the adjacent group of the next quartile (p50.050, one-sided).
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severity. The mean improvement in EQ-5D
utilities increased with increasing severity. The
standard deviations of the diﬀerences in utilities
were lower for SF-6D than for the EQ-5D utilities.
This resulted in SRMs for SF-6D utilities that
were at least twice as high as the SRMs for EQ-5D
utilities in all severity subgroups.
Discussion
In this paper, the ability of two diﬀerent pre-
ference-based measures to assess the health-related
quality of life in a group of patients suﬀering from
the most common mental health problems was
compared. The ability of the EQ-5D and the SF-
6D to discriminate between severity subgroups of
mental health patients was also studied. The
results of the overall comparison showed that
compared to SF-6D relatively more patients were
found at the upper end of the scale (no problems)
and fewer patients were found at the worst level on
the EQ-5D dimensions, except for the dimensions
of both instruments covering mental functioning.
Almost 65% reported having problems most of the
time or all of the time (the two highest levels) due
to mental health on the SF-6D, compared to 33%
who reported having extreme problems on the
anxiety/depression dimension of the EQ-5D. Over-
all, these ﬁndings correspond to the results found
by Brazier et al. [9] in a sample of patient with
seven diﬀerent medical conditions.
The diﬀerent responses of patients on related
dimensions of the instruments may (partly) be
explained by diﬀerences in the classiﬁcation
systems of the dimensions of the instruments.
With EQ-5D 243 health states can be distin-
guished, whereas SF-6D describes 18 000 diﬀerent
health states. In the algorithm developed by
Table 5. Mean improvement and SRM from baseline to 1 and 1.5 years follow-up for EQ-5D and SF-6D
Group based on SCL-90
scores quartiles n
Mean
improvement
SD
diﬀerence SRM
Mean
improvement
SD
diﬀerence SRM
EQ-5D: T1 year follow-upTbaseline SF-6D: T1 year follow-upTbaseline
1st quartile 91 0.073 0.273 0.267 0.093 0.149 0.621
2nd quartile 90 0.132 0.271 0.485 0.097 0.136 0.713
3rd quartile 92 0.173 0.349 0.496 0.096 0.138 0.699
4th quartile 82 0.240 0.377 0.636 0.100 0.122 0.823
Total 355 0.152 0.324 0.470 0.097 0.136 0.710
EQ-5D: T1.5 year follow-upTbaseline SF-6D: T1.5 years follow-upTbaseline
1st quartile 76 0.094 0.223 0.423 0.127 0.146 0.872
2nd quartile 86 0.105 0.308 0.339 0.094 0.127 0.739
3rd quartile 85 0.163 0.423 0.386 0.138 0.162 0.852
4th quartile 79 0.311 0.403 0.771 0.139 0.158 0.878
Total 326 0.167 0.359 0.466 0.124 0.149 0.833
SD, standard deviation. SRM, standardised response mean.
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Figure 1. Patterns of EQ-5D and SF-6D utilities across severity
subgroups
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Brazier and colleagues to calculate SF-6D prefer-
ences, not all diﬀerences in SF-6D health states are
translated into utility diﬀerences. In terms of
utilities, 3000 diﬀerent health states exist [4], which
is still much more than the 243 states of EQ-5D.
For some of the SF-6D dimensions, it is less
apparent that the succeeding levels produce one
continuum, because the various levels of one
dimension are composed using more than one
SF-36 item. For example, the physical functioning
dimension ranks the health of a patient with some
limitations in bathing and dressing as worse than
that of a patient experiencing a lot of limitations in
moderate activities.
To our knowledge, no previous studies have
been carried out examining the possible diﬀerences
in utilities on the EQ-5D and the SF-6D between
subgroups of patients with a diﬀerent degree of
severity of illness. Both the EQ-5D and the SF-6D
showed a decrease in utilities with increasing
severity. For both instruments mean utilities were
signiﬁcantly diﬀerent between all adjacent sub-
groups, thus demonstrating the ability of the
EQ-5D and SF-6D to discriminate between
severity subgroups of mental health patients.
However, the diﬀerence in mean utility between
the low and high severity subgroup is larger for
EQ-5D than for SF-6D, which is mainly caused by
the diﬀerence in mean utilities for the high severity
group. This result seems to support the ﬁndings of
Longworth and Bryan, who found that the SF-6D
was less suitable to describe the health states at the
lower end of the utility scale [10].
In order to explore the impact of using either the
EQ-5D or SF-6D in cost–utility analyses, we
examined changes in utilities for the patients on
both instruments from baseline until end of
treatment. Signiﬁcant diﬀerences were found
between the baseline and follow-up utilities on
both instruments for the entire study population as
well as the severity subgroups. Due to the smaller
standard deviations of the diﬀerences in SF-6D
utilities, the SRMs for the SF-6D were at least
twice as high for SF-6D compared tot EQ-5D.
However, in cost–utility analysis the mean im-
provements are used and not the SRMs. This
means that for the total study population and
three of the four severity subgroups the use of EQ-
5D results in a more favourable cost–utility ratio.
The greatest eﬀect of the choice between EQ-5D
and SF-6D on the cost–utility ratio was observed
for the high severity subgroup, which had the
largest diﬀerence in health gain. These results were
comparable with the ﬁndings of Pickard et al. [15]
in stroke.
Besides diﬀerences in their descriptive systems,
the EQ-5D and SF-6D valuation studies showed
diﬀerences that might (partly) explain these results.
EQ-5D health states were valued using the time
trade-oﬀ method (TTO), whereas the SF-6D
valuation study made use of the standard gamble
(SG). Various studies have shown that the SG
generally produces higher values than the TTO
[16,17]. The speciﬁc ‘chained’ variant of the SG
method used in the SF-6D valuation study was
expected to result in large overestimations of
utilities [18–21]. The resulting preferences could
then be corrected for this overestimation [22].
However, in the SF-6D valuation study no such
correction was reported [4]. This might explain the
relatively high preference score of 0.30 for
the worst possible SF-6D health state compared
to the score of 0.59 for the worst EQ-5D health
state. The larger range of the EQ-5D utility scale
provides a potential for the assessment of larger
health gains and also caused the higher standard
deviations of EQ-5D utilities compared to
SF-6D.
In conclusion, both EQ-5D and SF-6D could
discriminate between severity subgroups and
captured improvements in health over time.
However, the use of EQ-5D resulted in larger
health gains, which will be translated to lower
cost–utility ratios, especially for the subgroup with
the highest severity of mental health problems.
We concluded that the EQ-5D and the SF-6D are
to some extent interchangeable in cost–utility
analysis. This study illustrated that in populations
or subgroups with severe mental health problems
the results of cost–utility analyses can be aﬀected
by the choice of the instrument to measure health-
related quality of life. For this population, the
use of EQ-5D might result in more favourable
cost–utility ratios.
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